| Mehyar Hefazi Torghabeh, | |
|
4500 S Garnett Rd Ste 112, Tulsa, OK 74146-5201 | |
| (972) 665-8498 | |
| Not Available |
| Full Name | Mehyar Hefazi Torghabeh |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 4500 S Garnett Rd Ste 112, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548655343 | NPI | - | NPPES |
| Entity Name | Choctaw Nation Of Oklahoma |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659347623 PECOS PAC ID: 1759294838 Enrollment ID: O20031106000326 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Cherokee Nation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780692723 PECOS PAC ID: 5799698742 Enrollment ID: O20031106000628 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Claremore Indian Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073527842 PECOS PAC ID: 9436069911 Enrollment ID: O20031210001104 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Watonga Indian Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558458794 PECOS PAC ID: 9032010111 Enrollment ID: O20040120001001 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | El Reno Indian Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386725604 PECOS PAC ID: 5193627263 Enrollment ID: O20040121000487 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Clinton Indian Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205923448 PECOS PAC ID: 2163324237 Enrollment ID: O20040121000506 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Pawnee Indian Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629174081 PECOS PAC ID: 2769470160 Enrollment ID: O20040504001225 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Wewoka Indian Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689664195 PECOS PAC ID: 7517911415 Enrollment ID: O20050303000367 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Lawton Indian Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760489223 PECOS PAC ID: 6406800234 Enrollment ID: O20050304000301 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Anadarko Indian Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881637403 PECOS PAC ID: 7719931559 Enrollment ID: O20050304000365 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Carnegie Indian Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457459158 PECOS PAC ID: 1456456144 Enrollment ID: O20071217000184 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Laguna Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962001024 PECOS PAC ID: 2365855079 Enrollment ID: O20210119000388 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467053173 PECOS PAC ID: 5698786226 Enrollment ID: O20210226001928 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mehyar Hefazi Torghabeh, 4608 Nw 135th Cir, Vancouver, WA 98685-1567 Ph: (301) 281-1033 | Mehyar Hefazi Torghabeh, 4500 S Garnett Rd Ste 112, Tulsa, OK 74146-5201 Ph: (972) 665-8498 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
A new therapeutic target for the treatment of compulsive binge eating has been identified by researchers at Boston University School of Medicine.
In this interview, Marco Versiani discusses how he uses micro-CT in dentistry for the Root Canal Anatomy Project.
› Verified 6 days ago
Jonathan Cross, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 E 41st St Ste 900, Tulsa, OK 74135 Phone: 918-747-4975 Fax: 918-743-8552 | |
Dr. Kim R Hauger, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 E 41st St Ste 900, Tulsa, OK 74135 Phone: 918-747-4975 Fax: 918-743-8552 | |
Nina Jones, MD Radiology Medicare: Medicare Enrolled Practice Location: 4500 S Garnett Rd Ste 300, Tulsa, OK 74146 Phone: 918-728-6194 | |
Dr. Leila Danielle See, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 744 W 9th St, Tulsa, OK 74127 Phone: 981-599-5031 | |
Christopher Roman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4500 S Garnett Rd Ste 112, Tulsa, OK 74146 Phone: 918-935-3550 | |
Dr. Phillip Osborn Flinn, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 918-934-8347 Fax: 918-917-4114 | |
Shawn D Grant, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 918-579-7720 |